TAA-013

N/A

Report date: 2024/02/05 14:02:44

Base Information

Drug NameTAA-013

Drug Alias Name注射用TAA013TAA-013

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > SMCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesTot Biopharm Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A

Inactive CompaniesTot Biopharm Co Ltd

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A